A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in the very young and the old, has shown early promise in a Phase 1 clinical trial. The...

A Middle East respiratory syndrome coronavirus (MERS CoV) vaccine candidate was shown to be safe, well-tolerated, and induced a robust immune response in a Phase 1 first-in-human clinical trial. Initial...

Most people have probably been stung by a bee and while it can be painful, it’s especially dangerous for those at risk of suffering a life threatening allergic reaction.  Researchers have successfully...

By NewsDesk    @infectiousdiseasenews A three-day polio vaccination campaign took place in the province of Lunda Norte, according to Angolan press. The campaign vaccinated 205,688 children between...

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) hereby announce a new partnering agreement. With...

Biotech and vaccine development company, Valneva announced today the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15. The overall...

A more effective seasonal flu vaccine is about to be tested in clinical trials across the US. The current vaccine was 47 percent effective before a flu bug emerged halfway through the season, decreasing...

By NewsDesk  @infectiousdiseasenews Vietnam health officials recently reported (computer translated) on a 17-month-old girl from Ha Nam presenting to the hospital with high fever and a body rash. The...

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announced that it has signed an R&D...

Researchers at the University of North Carolina at Chapel Hill Gillings School of Global Public Health and their colleagues at the University of Texas at Austin and the National Institutes of Health Vaccine...